Fluticasone Furoate/GW642444

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 3

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

CompletedNCT01018186

GlaxoSmithKlineAsthma

Start: 2009-10-19End: 2011-05-12Updated: 2018-02-15

Asthma Exacerbation Study

CompletedNCT01086384

GlaxoSmithKlineAsthma

Start: 2010-02-22End: 2011-09-15Updated: 2018-01-24

Related Papers

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone

2017-09-01

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Respiratory Research2016-11-2311 citations

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.

2015-12-246 citations

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

Thorax2013-11-1984 citations

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

2013-02-2555 citations